Russell McCaig
Physician Assistant · El Dorado, KSNPI 1013983949
Payments from drug & device makers
Across 684 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$1K
- Pfizer$493
- plus $4K from 31 others
What the payments were for
- Food & beverage$10,912100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,754 |
| Lilly USA, LLC | 94 | $1,165 |
| AstraZeneca | 52 | $1,101 |
| Novo Nordisk | 74 | $1,037 |
| Amgen | 49 | $1,011 |
| Pfizer | 32 | $493 |
| Astellas Pharma US Inc | 26 | $460 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $435 |
| GSK | 22 | $401 |
| Merck | 23 | $368 |
| Amarin Pharma, Inc. | 16 | $260 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $234 |
| Bayer | 15 | $201 |
| Idorsia Pharmaceuticals US Inc | 12 | $190 |
| Abbott | 9 | $181 |
| Nestle Healthcare Nutrition Inc. | 5 | $176 |
| Biohaven Pharmaceuticals, Inc. | 15 | $175 |
| Johnson & Johnson | 8 | $121 |
| Daiichi Sankyo Inc. | 8 | $121 |
| Boehringer Ingelheim | 8 | $115 |
| Esperion Therapeutics, Inc. | 9 | $114 |
| Sanofi Pasteur Inc. | 7 | $108 |
| Novartis | 7 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Kowa Pharmaceuticals America, Inc. | 7 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Dexcom, Inc. | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Exeltis, USA Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Exact Sciences | 1 | $16 |
| Medtronic | 1 | $14 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$10,926 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 45 | $46,186 |
| FarxigaDapagliflozin Propanediol | 56 | $39,622 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $26,827 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,247 |
| JardianceEmpagliflozin | 36 | $24,458 |
| EliquisApixaban | 34 | $21,543 |
| OzempicSemaglutide | 18 | $18,948 |
| TrintellixVortioxetine Hydrobromide | 13 | $17,611 |
| XareltoRivaroxaban | 14 | $16,418 |
| MounjaroTirzepatide | 12 | $15,165 |
| LinzessLinaclotide | 17 | $14,445 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $11,224 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $9,405 |
| KerendiaFinerenone | 14 | $9,076 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,165 | $61,35157 claims |
| AstraZenecaFarxiga | $1,101 | $39,62256 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $115 | $32,02148 claims |
| GSKTrelegy Ellipta | $401 | $25,24738 claims |
| PfizerEliquis | $493 | $21,54334 claims |
| Novo NordiskOzempic | $1,037 | $18,94818 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $80 | $17,61113 claims |
| Johnson & JohnsonXarelto | $121 | $16,41814 claims |
| AbbVieLinzess | $1,754 | $14,44517 claims |
| BayerKerendia | $201 | $9,07614 claims |
| MerckJanumet Xr | $368 | $3,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in El Dorado
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Melissa WilkesFort Riley$13K
- Jenny MartensWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.